alovudine has been researched along with Lymphoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, BA; Hofman, MS; Prince, HM | 1 |
| Broccoli, A; Fanti, S; Fonti, C; Lambertini, A; Lodi, F; Nanni, C; Pellegrini, C; Stefoni, V; Zanoni, L; Zinzani, PL | 1 |
| Adler, S; Choyke, PL; Kurdziel, KA; Lindenberg, ML; Logan, J; Mena, E; Shih, J; Turkbey, BI; Wilson, W; Wong, K | 1 |
| Brepoels, L; De Groot, T; De Wolf-Peeters, C; Mortelmans, L; Stroobants, S; Verhoef, G | 1 |
| Agool, A; Huls, G; Olthof, S; Schuringa, JJ; Slart, RH; Smid, WM; Vellenga, E; Woolthuis, C | 1 |
| Buck, AK; Fayad, L; Graham, MM; Herrmann, K; Juweid, ME; Menda, Y; Tewson, T; Thomas, D | 1 |
| Bolen, JB; Chakravarty, A; Chen, W; Claiborne, CF; Ecsedy, JA; Germanos, MS; Gershman, RE; Hoar, KM; Huck, JJ; Hyer, ML; Janowick, DA; Leroy, PJ; Manfredi, MG; Sells, TB; Shinde, V; Silva, MD; Silverman, L; Stroud, SG; Wysong, DR; Zhang, M | 1 |
| Aboagye, EO; Barthel, H; Brady, F; He, Q; Latigo, J; Luthra, SK; Perumal, M; Price, PM | 1 |
| Bommer, M; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Juweid, M; Krause, BJ; Mattfeldt, T; Möller, P; Mottaghy, FM; Neumaier, B; Reske, SN; Schirrmeister, H; Stilgenbauer, S; Tepsic, D | 1 |
| Buck, AK; Neumaier, B; Reske, SN; Schmid, M; Vogg, AT; Wczasek, K; Zlatopolskiy, BD | 1 |
| Hicks, RJ | 1 |
| Egerer, G; Eisenhut, M; Gronkowski, M; Haberkorn, U; Haufe, S; Ho, AD; Kasper, B; Lehnert, T; Mechtersheimer, G | 1 |
| Bommer, M; Buck, AK; Glatting, G; Juweid, M; Kratochwil, C; Mattfeldt, T; Möller, P; Neumaier, B; Reske, SN; Tepsic, D; Vogg, AT | 1 |
1 trial(s) available for alovudine and Lymphoma
| Article | Year |
|---|---|
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2019 |
12 other study(ies) available for alovudine and Lymphoma
| Article | Year |
|---|---|
A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide "Marrow-Sparing" Radiotherapy.
Topics: Aged; Blood Cells; Bone Marrow; Cell Count; Dideoxynucleosides; Female; Humans; Lymphoma; Organ Sparing Treatments; Positron Emission Tomography Computed Tomography | 2019 |
A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.
Topics: Adult; Aged; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
(18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cyclophosphamide; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Lymphoma; Metabolic Clearance Rate; Mice; Mice, SCID; Protein Kinase Inhibitors; Protein Kinases; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Treatment Outcome | 2009 |
Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning.
Topics: Adult; Antigens, CD34; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Dideoxynucleosides; Follow-Up Studies; Granulocyte-Macrophage Progenitor Cells; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Molecular Imaging; Myeloid Progenitor Cells; Phenotype; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Transplantation, Autologous; Whole Body Imaging | 2011 |
PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity.
Topics: Dideoxynucleosides; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kidney Diseases; Liver Diseases; Lymphoma; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Tomography, Emission-Computed | 2010 |
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Topics: Animals; Aurora Kinase A; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Female; Fluorine Radioisotopes; HCT116 Cells; HeLa Cells; Humans; Lymphoma; Mice; Mice, Nude; Mice, SCID; Mitotic Index; Molecular Structure; Neoplasms; Phosphorylation; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Pyrimidines; Spindle Apparatus; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
Topics: Animals; Biomarkers, Tumor; Dideoxynucleosides; Lymphoma; Male; Metabolic Clearance Rate; Mice; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Thymidine Kinase; Tissue Distribution | 2005 |
Molecular imaging of proliferation in malignant lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Cell Growth Processes; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Tissue Distribution | 2006 |
Synthesis and biodistribution of 3'-fluoro-5-[(131)I]iodo-2'-deoxyuridine: a comparative study of [(131)I]FLIdU and [(18)F]FLT.
Topics: Animals; Cell Line, Tumor; Deoxyuridine; Dideoxynucleosides; Drug Evaluation, Preclinical; Humans; Isotope Labeling; Lymphoma; Metabolic Clearance Rate; Mice; Mice, SCID; Organ Specificity; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2007 |
The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?
Topics: Combined Modality Therapy; Data Interpretation, Statistical; Dideoxynucleosides; Disease-Free Survival; Humans; Lymphoma; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity | 2007 |
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2007 |
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.
Topics: Animals; Dideoxynucleosides; Humans; Lymphoma; Mice; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2007 |